Table 2. Baseline features and study endpoints in the two cohorts.
| Universitätsklinikum Dresden | University hospitals of the DSO eastern region other than the Universitätsklinikum Dresden | |||||||
|
Overall
n = 309) |
Reference period
(n = 164) |
Evaluation period
(n = 145) |
p |
Overall
(n = 1060) |
Reference period
(n = 529) |
Evaluationperiod
(n = 531) |
p | |
| Demographic variables | ||||||||
| Age (years; mean ± standard deviation) | 70.4 (14.4) |
71 (13.6) |
69.8 (15.3) |
0.48 | 69.2 (15.3) |
70.1 (15.1) |
68.3 (15.4) |
0.06 |
| Male patients (number and percent) | 183 (59.2%) |
96 (58.5%) |
87 (60%) |
0.79 | 624 (58.9%) |
316 (59.7%) |
308 (58%) |
0.57 |
| Type of brain damage (number and percent) | ||||||||
| Hemorrhagic stroke | 88 (28.5%) |
40 (24.4%) |
48 (33.1%) |
0.61 | 333 (31.4%) |
174 (32.9%) |
159 (29.9%) |
0.23 |
| Ischemic stroke | 106 (34.3%) |
58 (35.4%) |
48 (33.1%) |
318 (30%) |
160 (30.3%) |
158 (29.8%) |
||
| Trauma | 54 (17.5%) |
30 (18.3%) |
24 (16.6%) |
150 (14.2%) |
75 (14.2%) |
75 (14.1%) |
||
| Hypoxia/ischemia | 55 (17.8%) |
33 (20.1%) |
22 (15.2%) |
201 (19%) |
86 (16.3%) |
115 (21.7%) |
||
| Infection/inflammation | 2 (0.7%) |
1 (0.6%) |
1 (0.7%) |
17 (1.6%) |
9 (1.7%) |
8 (1.5%) |
||
| Other | 4 (1.3%) | 2 (1.2%) | 2 (1.4%) | 41 (3.9%) | 25 (4.7%) | 16 (3%) | ||
| Study endpoints (number, percent, 95% confidence interval) | ||||||||
| Undetected potential ILBF | 15 (4.9%) |
14 (8.5% [5.1; 13.9]) |
1 (0.7% [0.01; 4.2]) |
59 (5.6%) |
28 (5.3% [3.7;7.6]) |
31 (5.8%; [4.1; 8.2]) |
||
| ILBF | 31 (10%) |
11 (6.7% [3.7; 11.7]) |
20 (13.8% [9; 20.4]) |
105 (9.9%) |
46 (8.7% [6.6;11.4]) |
59 (11.1%; [8.7;14.1]) |
||
| Effectuated organ transplantation | 20 (6.5%) |
7 (4.3% [1.9; 8.7]) |
13 (9% [5.2; 14.9]) |
57 (5.4%) |
27 (5.1% [3.5; 7.4]) |
30 (5.7% [4;8]) |
||
| Report to DSO without organ transplantation | 23 (7.4%) |
9 (5.5% [2.8; 10.2]) |
14 (9.7% [5.7; 15.7]) |
110 (10.4%) |
49 (9.3% [7.1; 12.1]) |
61 (11.5% [9; 14.5]) |
||
DSO, German Organ Procurement Organization (Deutsche Stiftung Organtransplantation); ILBF, irreversible loss of brain function